STOCK TITAN

NuCana plc American Depositary Share - $NCNA STOCK NEWS

Welcome to our dedicated page for NuCana plc American Depositary Share news (Ticker: $NCNA), a resource for investors and traders seeking the latest updates and insights on NuCana plc American Depositary Share stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NuCana plc American Depositary Share's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NuCana plc American Depositary Share's position in the market.

Rhea-AI Summary
NuCana plc (Nasdaq: NCNA) will participate in the Truist Securities 2023 BioPharma Symposium on November 8-9, 2023, in New York, NY. The company's CEO, Hugh Griffith, and CFO, Don Munoz, will host one-on-one meetings at the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
conferences
-
Rhea-AI Summary
NuCana plc presents data from ongoing clinical studies with NUC-3373 in colorectal cancer at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.25%
Tags
none
-
Rhea-AI Summary
NuCana plc announces four presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
none
Rhea-AI Summary
NuCana plc (NASDAQ: NCNA) announced its financial results for the second quarter ended June 30, 2023. The company had cash and cash equivalents of £24.6 million as of June 30, 2023. NuCana reported a net loss of £5.4 million for the quarter. Data updates from all ongoing clinical studies are expected in the second half of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.86%
Tags
-
Rhea-AI Summary
NuCana to present at Jefferies Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
NuCana plc American Depositary Share

Nasdaq:NCNA

NCNA Rankings

NCNA Stock Data

8.27M
29.20M
0.56%
28.43%
0.31%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
3 Lochside Way

About NCNA

nucana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our phosphoramidate chemistry technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines. while these conventional agents remain part of the standard of care for the treatment of many solid tumours, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. utilising our proprietary protide technology, we are developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.